Viral infection is known to activate the RIG-I pathway and induce downstream Type I IFN production; however, the m6A modification of HBV, HCV (Kim et al.)[63], SARS-CoV-2 (Li et al.)[56], and HMPV RNA (Lu et al.)[57] in the region recognized by this receptor can inhibit the interaction with RIG-I and dampen the innate immune response to these pathogens. Here, RIGI is linked to viral infectious disease.